On November 5, Insulet recorded an Intraday Rise of 5.25% in Regular Trading, trading at $162.22 with turnover of $132 million.
The move followed the company’s latest quarterly report, which showed adjusted EPS of $1.99 versus the $1.59 consensus estimate and revenue of $842.0 million versus the $832.6 million expectation. Adjusted EPS was up from $1.24 a year earlier, while revenue increased from $706.3 million.
Insulet also maintained its full-year adjusted EPS growth outlook of more than 30% and said its board approved a $1 billion share repurchase program, with about $400 million expected to be repurchased in the fourth quarter using existing cash. The combination of an earnings beat, reaffirmed profitability outlook, and new capital return plan provides a clear near-term catalyst for the stock.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments